RecruitingNCT06512337
A Observational Study to Evaluate Deucravacitinib in Patients With Moderate Plaque Psoriasis in China
A Prospective Observational Study to Evaluate the Effectiveness of Deucravacitinib in Patients With Moderate Plaque Psoriasis in Real-World Settings in China (ADMIRE)
Sponsor
Bristol-Myers Squibb
Enrollment
150 participants
Start Date
Jan 20, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
The purpose of this study is to collect and evaluate real-world data on the effectiveness of deucravacitinib treatment in adults with moderate plaque psoriasis in China.
Eligibility
Min Age: 18 Years
Inclusion Criteria4
- Participant aged 18 years or older
- Physician-reported (dermatologist) diagnosis of moderate plaque psoriasis with Body Surface Area ≥ 3% and < 10%
- Participant newly initiated deucravacitinib according to the label
- Provided written informed consent to participate in the study
Exclusion Criteria3
- Participating in or planning to participate in an interventional clinical trial
- Concomitant use of other systemic treatments for psoriasis at baseline
- Prior treatment of deucravacitinib
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGDeucravacitinib
As per product label
Locations(5)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06512337
Related Trials
Study to Assess Change in Quality of Life of Risankizumab Treatment in Adult Participants With Moderate-to-Severe Plaque Psoriasis
NCT0703911064 locations
A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis
NCT0725080240 locations
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
NCT07116967350 locations
An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis
NCT0744970210 locations
Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis
NCT0729056926 locations